Search fresh public links, source activity, and post angles for Kalvista Pharmaceuticals.
Fresh curated links around KalVista Pharmaceuticals are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for here...
KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks from the rare disease hereditary angio...
The company announced it has concluded development of the plasma kallikrein inhibitor, which was being studied to treat diabetic macular edema.
Kiniksa Anonymous (not verified) Tue, 05/19/2026 - 08:34 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...
Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.
The deal hands Neurocrine a “controversial” medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, ac...
Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements...
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.
Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior versions of entrenched — but flawed — medicines for idio...
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
Image source: The Motley Fool. DATEWednesday, May 20, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Matthew GlineUnknown Executive (Mosliciguat program lead)Need a q...
Image source: The Motley Fool. DATEWednesday, May 20, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Matthew GlineUnknown Executive (Mosliciguat program lead)Need a q...
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked up from Verve Therapeutics, with the candidate now showing strong and consistent...
Rahway-based Merck announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201). It is a novel investigational bispecific antibody t...
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.